Literature DB >> 29460722

Cutaneous Toxicity in a Laboratory Beagle (Canis lupus familiaris) after Chronic Administration of Doxorubicin Hydrochloride.

Kathryn A Guerriero1, Steven R Wilson2, Nabil E Boutagy3, Chi Liu4, Albert J Sinusas5, Caroline J Zeiss1.   

Abstract

An adult female beagle (Canis lupus familiaris) used in a model of doxorubicin-induced cardiomyopathy presented with epithelial desquamation on the shoulders and ventrum after receiving the 8th weekly intravenous dose of the free form of doxorubicin (20 mg/m2; total accumulation, 160 mg/m2). The lesions were empirically treated with topical disinfectants and topical and systemic antibiotics. Despite treatment, the lesions progressed and ulcerated. Bacterial culture revealed Staphylococcus aureus, but trichogram, skin scraping, and fungal culture were negative for microorganisms. Skin biopsies revealed epidermal and apocrine gland hyperplasia, apocrine gland dilation, abnormal maturation of epithelial keratinocytes, and perivascular lymphocytic infiltration. These histopathologic findings resemble those in humans and canines after chronic administration of doxorubicin-containing pegylated liposomes. Here we report a clinical presentation after chronic administration of the free form of doxorubicin. In dogs, cutaneous toxicity after administration of pegylated liposomal doxorubicin is most often localized to the footpads, limbs, and axillary and urogenital regions. In the current case, lesions affected the ventrum and trunk but did not involve the footpads or axillary or urogenital regions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29460722      PMCID: PMC5824140     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  37 in total

1.  Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?

Authors:  U Jacobi; E Waibler; P Schulze; J Sehouli; G Oskay-Ozcelik; T Schmook; W Sterry; J Lademann
Journal:  Ann Oncol       Date:  2005-04-27       Impact factor: 32.976

2.  Eccrine squamous syringometaplasia secondary to pegylated liposomal doxorubicin.

Authors:  Xavier Garcia-Navarro; Lluis Puig; Maria T Fernández-Figueras; Agustíin Alomar
Journal:  Arch Dermatol       Date:  2008-10

3.  Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.

Authors:  R X Zhang; X J Wu; D S Wan; Z H Lu; L H Kong; Z Z Pan; G Chen
Journal:  Ann Oncol       Date:  2011-09-22       Impact factor: 32.976

Review 4.  Ceramide signalling: regulatory role in cell proliferation, differentiation and apoptosis in human epidermis.

Authors:  C C Geilen; T Wieder; C E Orfanos
Journal:  Arch Dermatol Res       Date:  1997-09       Impact factor: 3.017

5.  Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.

Authors:  S J Vukelja; W J Baker; H A Burris; J H Keeling; D Von Hoff
Journal:  J Natl Cancer Inst       Date:  1993-09-01       Impact factor: 13.506

6.  Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors.

Authors:  D M Vail; L D Kravis; A J Cooley; R Chun; E G MacEwen
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

Review 7.  Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.

Authors:  Lígia Traldi Macedo; Joao Paulo Nogueira Lima; Lucas Vieira dos Santos; Andre Deeke Sasse
Journal:  Support Care Cancer       Date:  2014-01-26       Impact factor: 3.603

Review 8.  Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.

Authors:  Adam D Lipworth; Caroline Robert; Andrew X Zhu
Journal:  Oncology       Date:  2009-11-16       Impact factor: 2.935

9.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

10.  In vitro study on the effect of doxorubicin on the proliferation markers MCM3 and Ki-67.

Authors:  S Etemad-Moghadam; S Fouladdel; E Azizi; M Alaeddini
Journal:  J BUON       Date:  2013 Oct-Dec       Impact factor: 2.533

View more
  1 in total

1.  Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.

Authors:  Chenxu Ni; Juemin Fang; Hong Qian; Qing Xu; Fuming Shen
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.